Aktienanalyse zu Altimmune Inc (ALT)ALTAltimmune Inc

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Altimmune Inc is a good buy right now due to its promising trial results for pemvidutide, which met key endpoints, and a strong analyst price target of $20, indicating significant upside potential. The current price is $3.11, and the stock has shown a 9.51% increase over the last 20 days, reflecting positive momentum. However, the main risk is the company's ongoing net losses, with a net income of -$22,825,000 reported for Q2 2026, which could impact investor sentiment if not addressed.

1 analysts cover ALT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.00.